Insurance Challenges and Costs Many private insurers are denying coverage for anti-obesity medications, creating a significant obstacle in treatment accessibility
The apitegromab group lost about the same total weight as the placebo group, but the composition of that weight loss was meaningfully different: 85% of the lost weight was fat in the apitegromab group, compared to 70% fat in the placebo group
The effect of tirzepatide on 24-hour mean systolic BP, diastolic BP, and heart rate (HR) measured during 24-hour ambulatory BP monitoring (ABPM) in individuals living with obesity without T2DM, has been evaluated in the SURMOUNT-1 ABPM sub-study.34 After 36 weeks of treatment, tirzepatide was associated with statistically significant and clinically meaningful reductions in the mean 24-hour systolic BP at all doses and reduced diastolic BP at the 2 lower doses.34 Simultaneously, tirzepatide treatment was associated with a dose-dependent increase in the mean 24-hour HR.34 Fortunately, there is no clear evidence that tirzepatide increases the risk of atrial fibrillation.35 5
Hashimotos Thyroiditis - Some patients may alternate between Graves' disease and Hashimotos, an autoimmune condition associated with an underactive thyroid
